October 11, 2023
WALTHAM, Mass. — Thea Pharma Inc. announced the launch and availability of Iyuzeh (latanoprost ophthalmic solution) 0.005% in the U.S. market. Preservative-free latanoprost, launched over 10 years ago, is available in 46 countries, mostly under the brand name Monoprost, with about 1.5 million patients treated monthly.1 Iyuzeh is the first and only preservative-free latanoprost for patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT) in the U.S. In randomized, controlled clinical trials of patients with POAG or OHT with mean baseline intraocular pressure (IOP) of 19-24 mmHg, Iyuzeh lowered IOP by 3-8 mmHg compared to 4-8 mmHg by Xalatan.2-4
“The U.S. launch of Iyuzeh is a major step forward for Théa Group, the eye care community, and patients,” said Jean-Frédéric Chibret, president of Théa. “Glaucoma is a chronic eye disease that affects the everyday lives of more than 60 million people globally. With Iyuzeh now available, eye care providers can effectively treat their POAG and OHT patients with preservative-free latanoprost. I would like to thank everyone involved in achieving this milestone – including the providers and patients who participated in the clinical studies, our teams, and each of our partners – for helping us deliver on our commitment to enable patients access to medication without preservatives.”
From enrollment to dispensing, Thea is committed to supporting eye care professionals and patients in every step of the access process. Iyuzeh (latanoprost ophthalmic solution) 0.005% is now available for as little as $60 for a 30-day supply through programs with PhilRx and the Thea Savings Card. For more information and eligibility requirements, please visit iyuzeh.com.
References
1 Théa. Data on file. 2023
2 Iyuzeh (latanoprost ophthalmic solution) 0.005%. Prescribing information. Thea Pharma Inc; 2022
3 Bacharach J, Ahmed IIK, Sharpe ED, Korenfeld MS, Zhang S, Baudouin C. Preservative-Free versus Benzalkonium Chloride–Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial. Clin Ophthalmol. 2023;17:2575-2588.
4 Rouland JF, Traverso CE, Stalmans I, et al. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Br J Ophthalmol. 2013;97(2):196–200. doi:10.1136/bjophthalmol-2012-302121
